Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas(Version 1.2024)Based on the Current Diagnosis and Treatment Status of China
Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas(Version 1.2024)Based on the Current Diagnosis and Treatment Status of China
张姗 1刘洁2
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 中国医学科学院北京协和医院皮肤科国家皮肤与免疫疾病临床医学研究中心,北京 100730
2. 中国医学科学院北京协和医院疑难重症及罕见病国家重点实验室,北京 100730
折叠
摘要
原发性皮肤淋巴瘤是一组异质性疾病,具有独特的临床表现及组织学特征,部分亚型的诊断与治疗存在挑战.2023年12月美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)更新发布了《NCCN指南:原发性皮肤淋巴瘤(2024年第1版)》,与2023年版指南比较,此次更新主要集中于诊断评估原则、分期标准、不同分期蕈样肉芽肿的治疗原则及对放疗的建议等方面.本文结合我国原发性皮肤淋巴瘤的诊疗现状及特点,对该指南的主要推荐内容进行解读,以促进其在我国临床实践中的应用.
Abstract
Primary cutaneous lymphomas are a group of non-Hodgkin's lymphomas originating from the skin,with unique clinical and histological features.In December 2023,the National Comprehensive Cancer Network(NCCN)updated and released the Clinical Practice Guidelines for Primary Cutaneous Lymphomas(Version 1.2024).Compared to the 2023 edition of the Guidelines,this update mainly focuses on the princi-ples of diagnostic assessment,staging criteria,treatment principles for mycosis fungoides(MF)at different stages,and recommendations for radiotherapy.In conjunction with the current situation and characteristics of the diagnosis and treatment of primary cutaneous lymphoma in our country,this article interprets the main rec-ommendations of the Guidelines to promote the application of clinical practices in our country.
维普
万方数据